Published : Apr-2020
No. of Pages : 153
1.1 List of Tables
1.2 List of Figures
2 Colorectal Cancer: Executive Summary
2.1 CRC Market is Expected to Grow to $8.1B in 2028
2.2 Avastin to Remain Leader despiteCompetition from Novel Mechanisms of Action
2.3 Unmet Need Will Remain for the Identification of New Targets and Biomarkers of Response
2.4 CRC Pipeline Moving Towards Precision Medicine in Both the Early and Metastatic Setting
2.5 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification or Staging Systems for CRC
4.3 Clinical Presentation
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources Used
5.4.2 Sources Not Used
5.4.3 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for CRC
5.5.1 Diagnosed Incident Cases of CRC
5.5.2 Age-Specific Diagnosed Incident Cases of CRC
5.5.3 Sex-Specific Diagnosed Incident Cases of CRC
5.5.4 Diagnosed Incident Cases of CRC by Stage at Diagnosis
5.5.5 Diagnosed Incident Cases of CRC by Molecular Markers
5.5.6 Diagnosed Incident Cases of CRC by Population with Curable Synchronous Liver Metastasis
5.5.7 Diagnosed Incident Cases of CRC by Sidedness
5.5.8 Five-Year Diagnosed Prevalent Cases of CRC
5.5.9 All-Time Diagnosed Prevalent Cases of CRC
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of the Analysis
5.6.3 Strengths of the Analysis
6 Disease Management
7 Competitive Assessment
7.1 Overview
8 Unmet Needs and Opportunity Assessment
9 Pipeline Assessment
10 Current and Future Players
11 Market Outlook
12 Appendix
List of Tables
Table 1: Colorectal Cancer: Key Metrics in the 8MM
Table 2: 8MM,TNM Staging and Classification for CRC
Table 3: Risk Factors and Comorbid Conditions Associated with CRC
Table 4: 8MM, Diagnosed Incident Cases of CRC by Molecular Markers, N, Both Sexes, Ages ?18 Years, 2018
Table 5: CRC Disease Management Across the 8MM
Table 6: Treatment Guidelines for CRC
Table 7: Leading Treatments for mCRC, 2018
Table 8: Roche's CRC Portfolio Assessment, 2020
Table 9: Amgen's CRC Portfolio Assessment, 2020
Table 10: Eli Lilly's CRC Portfolio Assessment, 2020
Table 11: Bayer's CRC Disease Portfolio Assessment, 2020
Table 12: Bristol-Myers Squibbs CRC Portfolio Assessment, 2020
Table 13: Merck KGA's CRC Disease Portfolio Assessment, 2020
Table 14: Merck & Co.'s CRC Disease Portfolio Assessment, 2020
Table 15: Novartis's CRC Disease Portfolio Assessment, 2020
Table 16: Pfizer's CRC Portfolio Assessment, 2020
Table 17: Sanofi's CRC Portfolio Assessment, 2020
Table 18: Taiho's CRC Disease Portfolio Assessment, 2020
Table 19: CRC Market - Global Drivers and Barriers, 2018-2028
Table 20: Key Events Impacting Sales for CRC in the US, 2018-2028
Table 21: CRC Drivers and Barriers in the US, 2018-2028
Table 22: Key Events Impacting Sales for CRC in the 5EU, 2018-2028
Table 23: CRC - Drivers and Barriers in the 5EU, 2018-2028
Table 24: Key Events Impacting Sales for CRC in Japan, 2018-2028
Table 25: CRC - Global Drivers and Barriers in Japan, 2018-2028
Table 26: Key Events Impacting Sales for CRC in China, 2018-2028
Table 27: CRC - Global Drivers and Barriers in China, 2018-2028
Table 28: Key Historical and Projected Launch Dates for CRC
Table 29: Key Historical and Projected Patent Expiry Dates for mCRC
Table 30: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
Figure 1: Global Sales Forecast by Country for CRC in 2018 and 2028
Figure 2: Analysis of the Company Portfolio Gap in CRC During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage CRC Pipeline Agents
Figure 4: Diagram of the Cancers of the Colon and Rectum
Figure 5: 8MM, Diagnosed Incidence of CRC (Cases per 100,000 Population), Men, Ages ?18 Years, 2018-2028
Figure 6: 8MM, Diagnosed Incidence of CRC (Cases per 100,000 Population), Women, Ages ?18 Years, 2018-2028
Figure 7: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC
Figure 8: 8MM, Sources Used to Forecast the Five-Year Diagnosed and Diagnosed Prevalent Cases of CRC
Figure 9: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of CRC by Stage at Diagnosis
Figure 10: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Molecular Markers
Figure 11: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Population with Curable Synchronous Liver Metastases
Figure 12: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Sidedness
Figure 13: 8MM, Diagnosed Incident Cases of CRC, N, Both Sexes, ?18 Years, 2018
Figure 14: 8MM, Age-Specific Diagnosed Incident Cases of CRC, N, Both Sexes, Ages ?18 Years, 2018
Figure 15: 8MM, Sex-Specific Diagnosed Incident Cases of CRC, N, Ages ?18 Years, 2018
Figure 16: 8MM, Diagnosed Incident Cases of CRC by Stage at Diagnosis, N, Both Sexes, Ages ?18 Years, 2018
Figure 17: 8MM, Diagnosed Incident Cases of CRC by Population with Curable Synchronous Liver Metastasis, N, Both Sexes, Ages ?18 Years, 2018
Figure 18: 8MM, Diagnosed Incident Cases of CRC by Sidedness, N, Both Sexes, Ages ?18 Years, 2018
Figure 19: 8MM, Five-Year Diagnosed Prevalent Cases of CRC, N, Both Sexes, Ages ?18 Years, 2018
Figure 20: 8MM, Diagnosed Prevalent Cases of CRC, N, Both Sexes, Ages ?18 Years, 2018
Figure 21: Unmet Needs and Opportunities in CRC
Figure 22: Overview of the Development Pipeline in CRC
Figure 23: Key Phase II/III Trials for Promising CRC Pipeline Agents
Figure 24: Competitive Assessment of the Late-Stage CRC Pipeline Agents
Figure 25: Analysis of the Company Portfolio Gap in mCRC During the Forecast Period
Figure 26: 8MM, Sales Forecast by Country for CRC in 2018 and 2028
Figure 27: 8MM, Sales Forecast by Drug Class for CRC in 2018 and 2028
Figure 28: Sales Forecast by Class for CRC in the US, 2018 and 2028
Figure 29: Sales Forecast by Class for CRC in the EU, 2018 and 2028
Figure 30: Sales Forecast by Class for CRC in Japan in 2018 and 2028
Figure 31: Sales Forecast by Class for CRC in China in 2018 and 2028
